WallStreetZenWallStreetZen

NASDAQ: ABCL
Abcellera Biologics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Abcellera Biologics earnings were -$144.0M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest ABCL earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$43.2M, up 382.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ABCL reported annual earnings of -$146.4M, with -10.1% growth.

ABCL earnings history

Current Revenue
$79.2M
Current Earnings
-$144.0M
Current Profit Margin
-181.7%

ABCL Return on Equity

Current Company
-14.9%
Current Industry
-141.9%
Current Market
13.5%
ABCL's Return on Equity (-14.9%)... subscribe to Premium to read more.
High Return on Equity Performance

ABCL Return on Assets

Current Company
-10.6%
Current Industry
-13.7%
ABCL is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ABCL announces earnings.

ABCL Return on Capital Employed

Current Company
-14.11%
Current Industry
-9.6%
ABCL's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ABCL vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ABCL-$146.92M-$143.96MN/A-$0.48
DMRA-$234.91M-$235.09M-63.52%$5.28
OCUL-$284.59M-$301.45MN/A-$1.40
AGIO-$394.04M-$411.29MN/A-$7.01
GENBN/AN/AN/AN/A
View Top Biotech Stocks

Abcellera Biologics Earnings Reports & History FAQ

What were Abcellera Biologics's earnings last quarter?

On ABCL's earnings call on May 7, 2026, Abcellera Biologics (NASDAQ: ABCL) reported Q1 2026 earnings per share (EPS) of -$0.14, up 6.67% year over year. Total ABCL earnings for the quarter were -$43.17 million. In the same quarter last year, Abcellera Biologics's earnings per share (EPS) was -$0.15.

If you're new to stock investing, here's how to buy Abcellera Biologics stock.

Is Abcellera Biologics profitable or losing money?

As of the last Abcellera Biologics earnings report, Abcellera Biologics is currently losing money. Abcellera Biologics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$143.96 million, a 14.24% decrease year over year.

What was ABCL's earnings growth in the past year?

As of Abcellera Biologics's earnings date in May 7, 2026, Abcellera Biologics's earnings has grown year over year. ABCL earnings in the past year totalled -$143.96 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.